Amber Tong

@AmberTongPW

Covering China biotech and pharma for Bloomberg News @business | formerly @endpts | views are my own | news and tips - [email protected]

Hong Kong

Joined June 2016

957Following

3KFollowers

Pinned

Amber Tong@AmberTongPW · Dec 3

In Chinese biotech circles, the idea of China as a "innovative drug supermarket" marks both opportunity and compromise. “I’ve never seen so many multinationals coming to China searching,” one insider says. Taking stock of one of 2024's biggest trends: bloomberg.com/news/articles/…

AmberTongPW's tweet card. At a time when geopolitical tensions are hitting industries from semiconductors to electric vehicles, pharmaceutical dealmaking has become a rare bright spot for collaboration between China and the...

9.0K

Pinned

Amber Tong@AmberTongPW · Jul 4

From brain rot to induced psychosis, the psychological cost of generative AI is growing and flying under the radar, @parmy writes bloomberg.com/opinion/articl…

AmberTongPW's tweet card. From brain rot to induced psychosis, the psychological cost of generative AI is growing and flying under the radar.

229

Amber Tong Retweeted

BioPharma Dive@BioPharmaDive · Jul 15

Cancer drugmaker LaNova to sell to China’s Sino Biopharm biopharmadive.com/news/lanova-si… by @NedPagliarulo

714

Amber Tong@AmberTongPW · Jul 14

For more history and color from Chinese biotech insiders, here's my 2021 story for @endpts endpoints.news/how-china-turn…

AAmber Tong@AmberTongPW · Jul 14

Chinese drugmakers have come a long way from their copycat days to challenge Western dominance on innovation. Our latest story visualizes this stunning advance, with data from @NorstellaCo with @hongjinshan and @spepechen: bloomberg.com/news/features/…

341

Amber Tong Retweeted

Satviki@satvicked · Jul 14

The number of novel drugs in China — for cancer, weight-loss and more — in development grew to over 1,250 last year, far surpassing the EU and nearly catching up to the US’s count of about 1,440, an exclusive Bloomberg News analysis showed. @AmberTongPW bloomberg.com/news/features/…

585

Amber Tong Retweeted

Bill Gates@BillGates · Jul 3

The facts are simple and devastating: Aid cuts have already cost lives, and the number of deaths will continue to rise. Here’s the evidence.

5.0K

26.0K

1.0K

5.4M

Amber Tong Retweeted

Jared Whitlock@Jared_Whitlock · Jul 2

One biotech VC calls China a threat. Another says Americans won’t forgive politicians who impede life-saving drugs. Inside the investor split on China’s ascent in drug development. endpoints.news/us-investors-d… w/ @AndrewE_Dunn + @maxonwifi, @ky_lahucik

534

Amber Tong@AmberTongPW · Jun 27

Innovent Wins China Nod For Obesity Drug Rivaling Novo, Lilly bloomberg.com/news/articles/…

AmberTongPW's tweet card. China approved Innovent Biologics Inc.’s closely watched weight loss drug Friday, unleashing a potent homegrown competitor against foreign giants Novo Nordisk A/S and Eli Lilly & Co.

274

Amber Tong Retweeted

Jason Mast@Jasonmmast · Jun 18

Nicole Verdun, director of the cell and gene therapy office, has been placed on forced out of the FDA statnews.com/2025/06/18/top…

6.0K

Amber Tong Retweeted

Ryan Cross the Science Boss@RLCscienceboss · Jun 10

Most biotech labs look the same. But I recently saw something incredible during my visit to the startup Bexorg: a human brain floating in a bucket, hooked up to a complex machine to keep its constituent cells alive. Read more in my deep dive for @endpts endpoints.news/rebooting-dead…

5.0K

Amber Tong@AmberTongPW · Jun 10

Remember Green Valley Pharmaceutical, the Chinese company that earned an approval for a homegrown Alzheimer’s drug out of nowhere in 2019? It has halted production and sales after the drug's license expired, pending renewal -- bloomberg.com/news/articles/…

342

Amber Tong Retweeted

Madeleine Armstrong@ByMadeleineA · Jun 2

$AMGN gets one over on $ZLAB in DLL3. Via @ApexOnco #ASCO25 oncologypipeline.com/apexonco/asco-…

4.0K

Amber Tong@AmberTongPW · Jun 2

More deals: Regeneron licenses GLP-1/GIP receptor agonist from Hansoh for $80 million upfront finance.yahoo.com/news/regeneron…

AmberTongPW's tweet card. New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China Phase 2 data suggest potentially similar...

5.0K

Amber Tong@AmberTongPW · Jun 2

Bristol-Myers Squibb will pay BioNTech as much as $11.1 billion to license PD-L1/VEGF bispecific initially licensed from Chinese biotech Biotheus @naomikresge bloomberg.com/news/articles/…

AmberTongPW's tweet card. Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as competition intensifies in an area of oncology that seeks to harness the immune...

289

Amber Tong@AmberTongPW · Jun 2

Sanofi to Buy Immunology Biotech Blueprint for $9.1 Billion (while Blueprint was once focused on precision cancer therapies and still has an oncology pipeline, Sanofi's release has 0 mention of the cancer work) with @ashleighfurlong @PhoebeSedge bloomberg.com/news/articles/…

AmberTongPW's tweet card. Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases.

384

Amber Tong@AmberTongPW · May 23

Top Chinese Drugmaker Hengrui Soars in Hong Kong Trading Debut bloomberg.com/news/articles/…

AmberTongPW's tweet card. Jiangsu Hengrui Pharmaceuticals Co., China’s largest drugmaker by market value, surged in its trading debut in Hong Kong after raising HK$9.9 billion ($1.3 billion) as listings pick up in the Asian...

3.0K

Amber Tong@AmberTongPW · May 20

Pfizer Licenses 3SBio Cancer Drug for Record $1.2 Billion PD-1/VEGF deal alert: bloomberg.com/news/articles/…

AmberTongPW's tweet card. Pfizer will pay $1.25 billion upfront to license an experimental cancer drug out of China, in a deal that underscores multinational drugmakers’ growing enthusiasm for Chinese biotech innovation.

434